Objective-In addition to P2Y 12 receptor antagonism, ticagrelor inhibits adenosine cell uptake. Prior data show that 7-day pretreatment with ticagrelor limits infarct size. We explored the acute effects of ticagrelor and clopidogrel on infarct size and potential long-term effects on heart function. Approach and Results-Rats underwent 30-minute ischemia per 24-hour reperfusion. (1) Ticagrelor (10 or 30 mg/kg) or clopidogrel (12.5 mg/kg) was given via intraperitoneal injection 5 minutes before reperfusion.
I n patients with acute coronary syndromes (ACSs), P2Y 12 receptor antagonists reduce the incidence of cardiovascular events. 1 A combination of aspirin with P2Y 12 receptor antagonists is recommended by the guidelines for patients with ACS, including ST-segment-elevation myocardial infarction (STEMI). 2-6 P2Y 12 receptor antagonists block ADP-induced platelet aggregation, which is one of the main amplification pathways of platelet activation. 1 The multicenter, randomized, placebo-controlled Platelet inhibition and patient Outcomes (PLATO) trial showed that added to aspirin, ticagrelor is associated with lower incidence of cardiovascular mortality, myocardial infarction, or stroke compared with clopidogrel in patients with ACS. 7, 8 Although the increased benefit was originally ascribed to better and more consistent platelet inhibition, ticagrelor, in addition to its P2Y 12 receptor-blocking properties, inhibits interstitial adenosine cell reuptake, via inhibition of the equilibrative nucleoside transporter 1, thereby increasing extracellular adenosine levels. [9] [10] [11] [12] Adenosine is a major mediator of myocardial protection against ischemia-reperfusion injury and is essential for the myocardial protection by ischemic preconditioning and various pharmacological preconditioning. 13, 14 We have recently shown that 7-day oral pretreatment with ticagrelor, but not clopidogrel, limits myocardial infarct size (IS) in rats subjected to 30-minute coronary artery ligation followed by 24-hour reperfusion. 15 Importantly, the degree of platelet inhibition was comparable between the clopidogrel and ticagrelor arms indicating a P2Y 12 -and platelet-independent cardioprotective effect of ticagrelor. Indeed, the protective effect was mediated by adenosine receptor activation with downstream phosphorylation of protein kinase B (Akt), endothelial NO synthase, and activation of cyclooxygenase-2 (COX2). 15 Thus, the data support that in addition to platelet inhibition, ticagrelor, but not clopidogrel, has protective effects against ischemia-reperfusion that may help explain the differences in clinical benefit in the PLATO trial. 7, 8 However, a recent multicenter, randomized, double-blind clinical trial did not show a clear clinical benefit in patients with STEMI receiving ticagrelor en route to the hospital versus in the catheterization laboratory. 16 As the study was not powered for benefit on cardiovascular events, it is inconclusive about the hypothesis that administration of ticagrelor after onset of ischemia (in contrast to pretreatment just before reperfusion) can ameliorate reperfusion injury. In addition, as the median time difference between the prehospital and the in-hospital ticagrelor administration groups was only 31 minutes, 16 it is plausible that ticagrelor absorption was insufficient and therefore, blood levels at the time of primary percutaneous coronary intervention (pPCI) were too low to protect the heart against reperfusion injury. Here, we asked (1) whether ticagrelor, administered intraperitoneal just before reperfusion, could limit IS in the rat and (2) whether ticagrelor can ameliorate adverse remodeling after infarction dependently or independently of its IS-limiting effect, and, thereby, improve heart function.
Materials and Methods
Materials and methods are available in the online-only Data Supplement.
Results

Ticagrelor, but Not Clopidogrel, Attenuates Reperfusion Injury
Rats underwent 30-minute coronary artery ligation followed by reperfusion. Ticagrelor (10 or 30 mg/kg), clopidogrel (12.5 mg/kg), or vehicle was given intraperitoneally 5 minutes before reperfusion. Area at risk was assessed by blue dye and IS by 2,3,5-triphenyltetrazolium chloride staining 24 hours after reperfusion. One rat in the ticagrelor 30 mg/kg and 1 in the clopidogrel group died during surgery (before administration of the study drugs). Hemodynamic data are presented in Figure IA in the online-only Data Supplement (heart rate) and Figure IB (mean blood pressure). Body weight and the size of the area at risk were comparable among groups (Table) . Ticagrelor dose-dependently reduced IS, expressed as percentage of the left ventricular weight (Table) or percentage of the area at risk ( Figure 1A ), whereas clopidogrel had no effect. IS (percentage of the area at risk) was significantly smaller in the ticagrelor 30 mg/kg than in the ticagrelor 10 mg/kg group (P=0.019). Ticagrelor plasma exposure 2 hours after reperfusion was 1.12±0.03 μmol/L in the ticagrelor 30 mg/kg group.
Both ticagrelor (10 and 30 mg/kg) and clopidogrel significantly inhibited ADP-induced platelet aggregation compared with the control group ( Figure 1B) . The effect of ticagrelor 30 mg/kg was significantly greater than that of ticagrelor 10 mg/ kg. The difference in level of inhibition between the clopidogrel (64.2%) and ticagrelor 30 mg/kg (61.5%) groups was not significant, suggesting that both drugs were equally effective in inhibiting P2Y 12 and platelet aggregation at these doses. In addition, 2 hours after reperfusion, tail vein bleeding time was equally prolonged by ticagrelor 30 mg/kg and clopidogrel ( Figure 1C ). Ticagrelor 30 mg/kg, but not clopidogrel, increased myocardial adenosine levels, a pharmacological marker of equilibrative nucleoside transporter 1 inhibition ( Figure 1D ).
The reperfusion injury induced an increased phosphorylation (enzyme activity) of the prosurvival mediators Akt (P-Akt), endothelial NO synthase (P-eNOS), and extracellular-signal-regulated kinase (ERK) 1/2 (P-ERK 1/2) 2 hours after reperfusion in the border zone, whereas the total enzyme levels remained constant ( Figure 2 ). Ticagrelor, but not clopidogrel, further increased the levels of P-Akt, P-endothelial NO synthase, and P-ERK 1/2 compared with the vehicle group ( Figure 2) .
The reperfusion injury also induced an increase in the COX2 mRNA levels 2 hours after reperfusion, which remained unaffected by both ticagrelor and clopidogrel ( Figure 3A ). However, ticagrelor significantly increased, whereas clopidogrel tended to decrease (P=0.05) COX2-dependent 6-keto-PGF1α production compared with the vehicle group ( Figure 3B ).
Twenty-four hours after reperfusion, apoptosis in the previously ischemic zone increased compared with the shamoperated animals ( Figure 3C ). Ticagrelor, but not clopidogrel, significantly decreased the number of apoptotic cells.
Ticagrelor, but Not Clopidogrel, Improved Remodeling After Ischemia-Reperfusion Injury
Next, we asked whether ticagrelor ameliorates adverse remodeling after infarction dependently or independently of its IS-limiting effect. This question was addressed by comparing the effect of acute treatment with chronic treatment initiated the day after reperfusion on heart function 4 weeks after reperfusion. We also evaluated whether the combined acute+chronic treatment would be additive.
At the end of the 4-week treatment period there were no significant differences in heart rate, body weight, and heart weight among the treatment groups ( Table II in the Data  Supplement) .
Echocardiographic data are presented in Figure 4 and Figure II in the online-only Data Supplement. Left ventricular internal diameter in diastole and systole significantly increased in the rats subjected to ischemia-reperfusion, whereas fractional shortening and left ventricular ejection fraction decreased. Acute or chronic (initiated the day after reperfusion) ticagrelor treatment normalized left ventricular internal diameter in diastole ( Figure 4A ). The effect of the combined acute+chronic ticagrelor treatment was comparable with that of acute and chronic alone. In contrast, clopidogrel (acute+chronic) had no effect at all. Ticagrelor, but not clopidogrel, also attenuated the increase in left ventricular internal diameter in systole but unlike data for left ventricular internal diameter in diastole with a significant additive effect of the combination ( Figure 4B ). Ticagrelor, but not clopidogrel, also improved the calculated parameters: left ventricular ejection fraction and fractional shortening ( Figure 4C and 4D). For left ventricular ejection fraction and fractional shortening, there was a numeric additive effect of the combination that did not reach statistical significance.
Ticagrelor plasma exposure after 7-day oral therapy was 1.43±0.05 and 4.21±0.09 μmol/L in the 150 and 300 mg/kg per day group, respectively. In parallel, ticagrelor significantly inhibited ADP-induced platelet aggregation by 53.5% and 69.7%, respectively. The level of inhibition, at 300 mg/kg per day, was equal to that of clopidogrel (70.9%; Figure 5A ).
Myocardial fibrosis increased in the rats that underwent ischemia-reperfusion injury when evaluated 4 weeks after reperfusion. All 3 ticagrelor regimes, but not clopidogrel, reduced fibrosis with significantly greater reduction with chronic versus acute treatment (P=0.002), and there was no additional effect of the combination ( Figure 5B ; Figure III in the online-only Data Supplement). Collagen III mRNA levels increased significantly in the group exposed to ischemia-reperfusion. All 3 ticagrelor regimes significantly decreased collagen III mRNA levels with no significant difference between treatments, whereas clopidogrel had no effect ( Figure 5C ).
The mRNA levels of the proinflammatory mediators, tumor necrosis factor-α (TNFα), interleukin (IL)-1β, and IL-18, increased in the myocardial border zone 4 weeks after reperfusion ( Figure 6A -6C). All 3 ticagrelor regimens significantly reduced the levels of all these mediators with no significant difference among treatments, whereas clopidogrel had no effect.
Myocardial levels of the anti-inflammatory eicosanoid 15-epi-lipoxin A 4 remained unchanged 4 weeks after reperfusion (7.3±0.7 versus 7.6±0.3 pg/µg). Chronic (17.2±0.5 pg/µg; P<0.001) or combined acute+chronic ticagrelor treatment (17.4±0.7 pg/µg; P<0.001) significantly increased 15-epilipoxin A 4 levels, whereas clopidogrel (7.3±0.6 pg/µg; P=1.0) and acute ticagrelor (8.3±0.7 pg/µg) had no effect.
Myocardial macrophage inflammatory protein-2 (MIP-2; Figure 6D ) and fibroblast growth factor-2 (FGF-2; Figure 6E ) levels increased 4 weeks after reperfusion. Acute ticagrelor treatment tended to reduce MIP-2 levels (P=0.93) and significantly reduced FGF-2 levels (P=0.02). Chronic ticagrelor significantly reduced MIP-2 and FGF-2 levels, with no significant additional effect of the combination. Clopidogrel had no effect on MIP-2 levels (P=1.00 versus vehicle), but completely normalized FGF-2 levels (P=1.0 versus the sham group).
Discussion
The main findings of the present study are that acute ticagrelor treatment just before reperfusion increased myocardial adenosine levels, augmented the phosphorylation of the prosurvival kinases Akt and ERK 1/2 and endothelial NO synthase, and limited myocardial IS. This cardioprotective effect of a single acute dose of ticagrelor translated into an improved heart function and reduced fibrosis and collagen III expression 4 weeks later. Similar effects on heart function fibrosis and collagen III, along with attenuation of the increase in proinflammatory mediators, was seen with chronic oral ticagrelor therapy, started the day after reperfusion, and with the combination of acute and chronic oral treatment. In contrast, clopidogrel, despite achieving similar degree of inhibition of platelet aggregation, did not display any acute cardioprotective effect or improved long-term heart function.
The mean maximal ticagrelor plasma exposure (Cmax) reported in patients after 4 weeks of treatment with the standard dose of 90 mg BID is 1.4 μmol/L with a SD of 0.7 μmol/L. 15, 17 Thus, the experiments reported here were conducted at clinically relevant ticagrelor plasma exposure levels (1.12 and 1.43 μmol/L in 30 mg/kg IP and 150 mg/kg per day oral), except for a slightly supratherapeutic exposure after 300 mg/kg per day oral (4.21 μmol/L). Considering the lack of effect seen for clopidogrel, dosed to a similar platelet inhibition, suggests that the protective effects seen with ticagrelor are independent of platelet and P2Y 12 inhibition.
The current data confirm our previous findings that ticagrelor, but not clopidogrel, increases myocardial adenosine levels. 15 Higher plasma adenosine levels have also been documented in patients with ACS treated with ticagrelor than in those receiving clopidogrel. 10 Adenosine mediates myocardial protection by ischemic preconditioning and various pharmacological preconditioning. 13, 14 We have recently shown that the protective effects of ticagrelor pretreatment against ischemiareperfusion injury are dependent on adenosine receptor activation. 15 In addition to its role in preconditioning, adenosine is also essential for the cardioprotective effect of postconditioning. 14 Two large multicenter studies (the Acute Myocardial Infarction Study of Adenosine [AMISTAD] I and AMISTAD II) demonstrated that high-dose intravenous infusion of adenosine, started before reperfusion, significantly reduced IS in patients with anterior wall STEMI. 18, 19 However, the primary end point of new congestive heart failure beginning >24 hours after randomization, the first rehospitalization for heart failure, or death from any cause within 6 months was not reduced by adenosine therapy in the AMISTAD-II trial, 19 whereas there was a trend toward increasing adverse clinical end points with adenosine in the smaller AMISTAD-I trial. 18 In AMISTAD-II intravenous administration of adenosine was associated with an increased rate of hypotension 19 that may explain the dissociation between the favorable effect on IS and the lack of benefit concerning clinical outcomes. Nevertheless, in a retrospective analysis of patients who achieved reperfusion within 3.17 hours of onset of symptoms, adenosine, compared with placebo, significantly reduced mortality. 20 Two recent clinical trials did not show to demonstrate beneficial effects of intracoronary adenosine before reperfusion on myocardial IS. 21, 22 A likely explanation is that the short half-life of adenosine in the circulation makes intracoronary bolus injections ineffective. 14 In contrast to intravenous adenosine, ticagrelor increases adenosine levels at sites with increased production by preventing its reuptake. The effect should be sustained as long as sufficient ticagrelor exposure is present. [9] [10] [11] [12] In a previous study we showed that 7-day pretreatment with ticagrelor upregulated COX2 expression and activity. 15 The protective effect of ticagrelor pretreatment was blocked with specific COX2 inhibitors, as well as aspirin. 15 In the present study, acute ticagrelor treatment just before reperfusion did not increase COX2 mRNA levels 2 hours after reperfusion. The role of COX2 in mediating the second window of protection by ischemic preconditioning and various pharmacological agents is well established. 23 Yet, the significance of COX2 in mediating the protective effects of postconditioning against reperfusion injury is less certain. 23, 24 Here, we show that although COX2 mRNA levels were not changed by ticagrelor and clopidogrel 2 hours after reperfusion, ticagrelor significantly increased COX2 activity. Statins induce adenosine receptor-dependent COX2 activation via S-nitrosylation. 25, 26 This mode of COX2 activation is probably a prompt response, before COX2 mRNA and protein expression are increased. It remains to be explored whether ticagrelor-induced COX2 activation, described here, works via the same or similar mechanism.
Unlike ticagrelor, acute clopidogrel treatment failed to limit IS, which further supports the lack of cardioprotective effect of clopidogrel in our previous study evaluating 7-day pretreatment. 15 Yang et al 27 reported that 2-day pretreatment with clopidogrel and intravenous cangrelor, started before reperfusion, reduced IS in rabbits subjected to 30 minutes of ischemia per 3 hours of reperfusion. However, clopidogrel had no effect when administered only 24 hours before ischemia. They report that the protective effect was independent of the antiplatelet effects of the drugs, but was attenuated by adenosine receptor blockers and phosphoinositide 3-kinase/ Akt inhibitors. 27 The differences between the study by Yang et al and our studies are unclear. Cangrelor and clopidogrel, in contrast to ticagrelor, do not inhibit cellular adenosine uptake via equilibrative nucleoside transporter 1. 9 Differences between species (rats versus rabbits), dose, or the length of reperfusion (3 versus 24 hours) may be the explanation. Wang et al, 28 however, compared the effect of intravenous ticagrelor and clopidogrel, added to intravenous thrombolytic therapy with tissue-type plasminogen activator in dogs with electrolytic injury-induced intracoronary thrombus. They found that ticagrelor, but not clopidogrel, limits myocardial IS. As both ticagrelor and clopidogrel were dosed to complete inhibition of ex vivo ADP-induced aggregation, as in our study, they also raised the possibility that the beneficial effect could be mediated by mechanisms independent of platelet inhibition, including inhibition of vascular P2Y 12 receptors or via adenosine uptake inhibition. 28 Patti et al 29 compared the effect of a 600-versus a 300-mg loading dose of clopidogrel on IS in patients who underwent pPCI for STEMI. The high dose of clopidogrel was associated with lower levels of creatine kinase MB and troponin-I, better TIMI (thrombolysis in myocardial infarction) flow grade, and improved left ventricular ejection fraction at discharge. However, these results may be attributed to better and more rapid platelet inhibition. In our model, myocardial infarction is induced by mechanical ligation of the coronary artery; and hence, the role of platelet inhibition is probably less significant.
Importantly, we found that the acute cardioprotective effect against reperfusion injury mediated by ticagrelor translated into improved heart function 4 weeks later. Surprisingly, Table II in the online-only Data Supplement). C, Myocardial collagen III mRNA expression 4 weeks after reperfusion. *P<0.001 vs vehicle; †P<0.001 vs TIC IP+oral (n=4-5 per group). P values shown in the graphs are for the overall differences among groups (ANOVA). Downloaded from http://ahajournals.org by on November 22, 2019 a similar beneficial effect on heart function was seen with chronic treatment initiated 1 day after reperfusion, thus independent of its IS-limiting effect, with minor additive effect when acute and chronic treatments were combined. In contrast, Yang et al 27 reported that the protective effect of cangrelor was lost when the drug infusion started 10 minutes after reperfusion compared with drug infusion before reperfusion.
As differences in angiographic findings, secondary to greater platelet inhibition, cannot explain the differences in clinical outcomes between ticagrelor and clopidogrel in the PLATO trial, 30, 31 our study may provide an alternative explanation. In addition to its antiplatelet effects, ticagrelor provides cardioprotection against ischemia-reperfusion injury and improve long-term remodeling after infarction. The recent Administration of Ticagrelor in the Cath Laboratory or in the Ambulance for New ST-Elevation Myocardial Infarction to Open the Coronary Artery (ATLANTIC) trial failed to show a clear clinical benefit in patients with STEMI undergoing pPCI and receiving ticagrelor en route to the hospital versus in the catheterization laboratory. 16 The myocardial reperfusion in angioplasty of patients with STEMI loaded with ticagrelor or clopidogrel (MICAMI-TICLO) trial 31 showed that ticagrelor loading before pPCI for STEMI did not improve angiographic findings or ST-segment elevation resolution, as compared with clopidogrel loading. In both trials, the time from drug loading to intervention was short (31-43 minutes). 16, 31 It is plausible that the time between dose and pPCI in the in-ambulance study arm was insufficient to allow significant ticagrelor exposure at the time of pPCI to induce adenosine-dependent protection against the acute reperfusion injury, as shown in the current rat study. The MICAMI-TICLO trial was relatively small and did not follow the patients for clinical outcomes. 31 However, both groups in the ATLANTIC trial received chronic ticagrelor treatment; hence, both groups benefited from the long-term effects of the drug. Therefore, no between-group difference could be seen. 16 Considering our data, which show a benefit of both acute and chronic treatments, and these clinical data, which have not been able to make the comparison, the relative benefit from acute and chronic ticagrelor treatments in patients remains to be defined.
A single dose of ticagrelor, administered intraperitoneally before reperfusion, reduced IS, and as a consequence, inflammation, fibrosis, and remodeling 4 weeks after infarction. In contrast, the effect of the 4-week chronic treatment cannot be attributed to direct protection against reperfusion injury, as at the time therapy started, cell death because of ischemia and reperfusion was completed. It is thus plausible that ticagrelor, via its adenosine augmentation effects, ameliorated inflammation and attenuated adverse remodeling. It is clear that these favorable effects are independent of the antiplatelet properties of ticagrelor, as clopidogrel had no effect on inflammation, fibrosis, and remodeling despite achieving a similar degree of platelet aggregation inhibition. TNFα, 32, 33 IL-1β, 33, 34 and IL-18 [34] [35] [36] are involved in myocardial ischemia-reperfusion injury and remodeling. Thus, the reduction of these proinflammatory mediators induced by ticagrelor may explain the favorable effects on fibrosis and remodeling. It has been reported that activation of the adenosine A1 receptors attenuates the prohypertrophic effects of TNFα on cardiomyocytes, 37 and that adenosine suppresses TNFα expression. 38 Ticagrelor increased myocardial levels of 15-epi-lipoxin A 4 , an eicosanoid mediator with potent anti-inflammation effects, 15 that has been shown to inhibit TNFα and IL1β secretion and to attenuate the effects of TNFα. [39] [40] [41] Future studies are needed to explore whether the effects of ticagrelor on the expression of the proinflammatory mediators are dependent on the upregulation of 15-epi-lipoxin A 4 levels. As the synthesis of 15-epilipoxin A 4 is dependent on COX2, these anti-inflammatory effects of ticagrelor might be COX2 dependent and could be potentially inhibited by high-dose aspirin. 15 MIP-2 is a proinflammatory chemokine that increases after ischemia-reperfusion injury and infarction and may be involved in adverse cardiac remodeling. 42, 43 Here, we show that ticagrelor, but not clopidogrel, attenuates the increase in MIP-2 4 weeks after myocardial infarction. However, FGF-2 induces cardioprotection, 44 has a role as a chemotactic factor for stem cell homing after myocardial injury, 45 induces angiogenesis, 46, 47 and improves remodeling after myocardial infarction in the rat. [48] [49] [50] The significance of the ticagrelorinduced attenuation and clopidogrel-induced normalization of the increase in FGF-2 levels 4 weeks after infarction is unclear. Although ticagrelor attenuated adverse remodeling after infarction, clopidogrel had no effect. It is possible that 4 weeks after infarction, healing was better in the ticagrelortreated animals and therefore, the stimulus for FGF-2 release was decreased. In contrast, as clopidogrel had no effect on adverse remodeling, its normalization of the FGF-2 levels may have adverse effects. Further studies are needed to clarify the effects of these drugs on FGF-2 release over time after infarction and their pathophysiologic significance.
Here, we are showing that acute administration of ticagrelor before reperfusion reduces myocardial IS. The challenge in the clinical setting is how to get sufficient drug exposure before pPCI, as the average time between first medical encounter and reperfusion is relatively short. Parenteral (intravenous) or chewable formulation should probably be developed for this purpose. This may be less a problem in non-ST elevation ACSs, as the time from first medical encounter to PCI is longer. One may question the role of chronic treatment if the initial acute effects could be achieved by reaching adequate drug exposure at the time of reperfusion. In our models, the only parameter that showed greater improvement with the acute and chronic ticagrelor treatments as compared with acute treatment alone or chronic treatment alone was left ventricular internal diameter in systole. However, the animals in our models do not have atherosclerosis and coronary occlusion was induced by mechanical ligation of the artery. Thus, the role of platelet aggregation in mediating acute reperfusion injury, and over the long run, new coronary lesions, including acute thrombotic occlusion of coronary arteries, is much less important in our model than in the clinical setting. Thus, in the current model, we do not compare the effects of outcomes of chronic antiplatelet inhibition with ticagrelor versus clopidogrel, but only study acute cardioprotection and subsequent effects on remodeling. Importantly, our experiments indicate that even if optimal ticagrelor exposure cannot be achieved at the time of pPCI, oral therapy started after reperfusion could still improve heart function. This effect on remodeling after infarction should be further studied. It is plausible that the effects of chronic exposure on remodeling after infarction (along with better and more reliable antiplatelet effects) are the explanation of the superiority of ticagrelor over clopidogrel in the PLATO trial.
Based on the results of the current study, we have initiated a clinical trial comparing the effects of ticagrelor and another P2Y 12 receptor antagonist on myocardial IS in patients with first anterior STEMI undergoing pPCI. Further studies are probably needed to search for alternative mode of administration (chewable, intravenous, or even higher loading dose) to achieve effective ticagrelor blood levels by the time reperfusion occurs. Additional studies are needed to evaluate the effects of ticagrelor treatment on cardiac remodeling and heart function after myocardial infarction.
In addition to ticagrelor, 2 other antiplatelet agents, dipyridamole 51, 52 and cilostazol, 53 also prevent the reuptake of adenosine and have been shown to limit myocardial IS. However, both also inhibit phosphodiesterase-III, increasing intracellular levels of cAMP making comparisons difficult. Also in addition to ticagrelor, the other P2Y 12 antagonists, clopidogrel and prasugrel, can attenuate platelet-leukocyte interactions and modulate inflammatory response. 54 Yet, in our model, ticagrelor, but not clopidogrel, limited IS and improved postinfarction remodeling, despite similar platelet inhibition by both drugs. No data are available for prasugrel in this regard.
Limitations
The number of animals in each group is small (especially when compared with the number of patients in each group in clinical trials). However, these sample sizes are commonly used in animal studies and are based on experience and sample size calculation. The animals used in bench research are more homogeneous (age, sex, weight, and genetic background) than the typical patient populations and they are exposed to exactly same insult (ischemic time, reperfusion time, etc). The results of the current study should be verified in other animal models and in clinical trials before they are implemented for patient care.
In conclusion, ticagrelor, administered just before reperfusion, provided acute cardioprotection and limited IS. This acute cardioprotective effect translates into long-term improved heart function. In addition, also chronic ticagrelor treatment initiated the day after reperfusion improved heart function independently of the acute IS-limiting effect. Clopidogrel, despite achieving similar degree of platelet inhibition, had no acute or chronic cardioprotective effects. The results should be confirmed in appropriate clinical studies, as frequently, positive findings from animal models are not translated to clinical benefits in patients. 55
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